154660-48-7

Basic information

• Product Name: 2-PHENYLBENZHYDRAZIDE
• Synonyms: [1,1,-biphenyl]-2-carbohydrazide;2-BIPHENYLCARBOXYLIC ACID HYDRAZIDE;2-BIPHENYLCARBOXYLIC HYDRAZIDE;2-PHENYLBENZHYDRAZIDE;BIPHENYL-2-CARBOHYDRAZIDE
• CAS NO: 154660-48-7
• Molecular Formula: C₁₃H₁₂N₂O
• Molecular Weight: 212.25
• Mol File: 154660-48-7.mol

Chemical Properties

• Melting Point: 140 °C
• Appearance: /
• Density: 1.164 g/cm³
• Refractive Index: 1.612
• PKA: 12.49±0.10(Predicted)
• CAS DataBase Reference: 2-PHENYLBENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PHENYLBENZHYDRAZIDE(154660-48-7)
• EPA Substance Registry System: 2-PHENYLBENZHYDRAZIDE(154660-48-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 154660-48-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis Industry:
2-PHENYLBENZHYDRAZIDE is used as an intermediate for the production of various dyes and pigments, contributing to the coloration and stability of these products in different applications.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 2-PHENYLBENZHYDRAZIDE is utilized as a key component in the synthesis of various medicinal compounds, playing a crucial role in drug development and formulation.
Used in Agrochemical Industry:
2-PHENYLBENZHYDRAZIDE is also employed as an intermediate in the synthesis of agrochemicals, aiding in the development of products for agricultural applications such as pesticides and fertilizers.
Used in Rubber and Plastics Industry:
2-PHENYLBENZHYDRAZIDE is used as a reducing agent and antioxidant in the rubber and plastics industry, enhancing the durability and performance of these materials by preventing degradation and improving their stability.
Given the compound's potential toxicity, it is essential to handle 2-PHENYLBENZHYDRAZIDE with care to minimize exposure and avoid adverse health effects.

InChI:InChI=1/C13H12N2O/c14-15-13(16)12-9-5-4-8-11(12)10-6-2-1-3-7-10/h1-9H,14H2,(H,15,16)

Upstream product

• 16605-99-5 biphenyl-2-carboxylic acid methyl ester 
• 947-84-2 2-Biphenylcarboxylic acid 
• 19926-49-9 2-phenylbenzoic acid ethyl ester 

Downstream Products

• 154660-49-8 N-(2-phenylbenzoyl)-N'-benzensulfonylhydrazine 
• 474973-50-7 Biphenyl-2-carboxylic acid (3-trifluoromethyl-benzylidene)-hydrazide 
• 486-25-9 9-fluorenone 
• 1260172-91-5 3-(biphenyl-2-yl)-4-(2-fluorophenyl)-5-methyl-4H-1,2,4-triazole 
• 154660-55-6 (+/-)-2-(2-phenylbenzylidene)-3-(2-methoxybenzylamino)quinuclidine 
• 154660-54-5 (+/-)-2-(2-phenylbenzylidene)-3-(benzylamino)quinuclidine 
• 154660-50-1 (Z)-2-(2-phenylbenzylidene)-3-quinuclidinone 
• 1203-68-5 2-Phenylbenzaldehyde 
• 1015-89-0 6(5H)-phenanthridinone 

Relevant articles and documents

Phosphine-free ruthenium complex-catalyzed synthesis of mono- Or dialkylated acyl hydrazides via the borrowing hydrogen strategy

Herein, we report a diaminocyclopentadienone ruthenium tricarbonyl complex-catalyzed synthesis of mono- or dialkylated acyl hydrazide compounds using the borrowing hydrogen strategy in the presence of various substituted primary and secondary alcohols as alkylating reagents. Deuterium labeling experiments confirm that the alcohols were the hydride source in this cascade process. Density functional theory (DFT) calculations unveil the origin and the threshold between the mono- and dialkylation.

Ruthenium-Catalyzed Three-Component Alkylation: A Tandem Approach to the Synthesis of Nonsymmetric N,N-Dialkyl Acyl Hydrazides with Alcohols

The borrowing hydrogen strategy has been applied in the synthesis of nonsymmetric N,N-dialkylated acyl hydrazides via a tandem three-component reaction catalyzed by a phosphine free diaminocyclopentadienone ruthenium tricarbonyl complex. This strategy represents the first direct one-pot approach to nonsymmetric functionalized acyl hydrazides. Different aromatic acyl hydrazides underwent dialkylation with a variety of primary or secondary alcohols and methanol or ethanol as alkylating agents in mild reaction conditions and good yields. Deuterium labelling experiments suggested that the primary or secondary alcohol was the hydrogen source in this tandem process. DFT calculations show that the combination of the tandem mixed product cannot be perfectly explained neither structurally nor electronically, but might be dependent of the physical state of the aldehyde or ketone intermediate (gaz vs. liquid) at the reaction temperature. (Figure presented.).

1,2,4-Triazole-3-thione compounds with a 4-ethyl alkyl/aryl sulfide substituent are broad-spectrum metallo-β-lactamase inhibitors with re-sensitization activity

Metallo-β-lactamases (MBLs) are important contributors of Gram-negative bacteria resistance to β-lactam antibiotics. MBLs are highly worrying because of their carbapenemase activity, their rapid spread in major human opportunistic pathogens while no clinically useful inhibitor is available yet. In this context, we are exploring the potential of compounds based on the 1,2,4-triazole-3-thione scaffold as an original ligand of the di-zinc active sites of MBLs, and diversely substituted at its positions 4 and 5. Here, we present a new series of compounds substituted at the 4-position by a thioether-containing alkyl chain with a carboxylic and/or an aryl group at its extremity. Several compounds showed broad-spectrum inhibition with Ki values in the μM to sub-μM range against VIM-type enzymes, NDM-1 and IMP-1. The presence of the sulfur and of the aryl group was important for the inhibitory activity and the binding mode of a few compounds in VIM-2 was revealed by X-ray crystallography. Importantly, in vitro antibacterial susceptibility assays showed that several inhibitors were able to potentiate the activity of meropenem on Klebsiella pneumoniae clinical isolates producing VIM-1 or VIM-4, with a potentiation effect of up to 16-fold. Finally, a selected compound was found to only moderately inhibit the di-zinc human glyoxalase II, and several showed no or only moderate toxicity toward several human cells, thus favourably completing a promising behaviour.

Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction

Defective in cullin neddylation 1(DCN1) is a co-E3 ligase that is important for cullin neddylation. Dysregulation of DCN1 highly correlates with the development of various cancers. Herein, from the initial high-throughput screening, a novel hit compound 5a containing a phenyltriazole thiol core (IC50 value of 0.95 μM for DCN1-UBC12 interaction) was discovered. Further structure-based optimization leads to the development of SK-464 (IC50 value of 26 nM). We found that SK-464 not only directly bound to DCN1 in vitro, but also engaged cellular DCN1, suppressed the neddylation of cullin3, and hindered the migration and invasion of two DCN1-overexpressed squamous carcinoma cell lines (KYSE70 and H2170). These findings indicate that SK-464 may be a novel lead compound targeting DCN1-UBC12 interaction.

4-Amino-1,2,4-triazole-3-thione-derived Schiff bases as metallo-β-lactamase inhibitors

Resistance to β-lactam antibiotics in Gram-negatives producing metallo-β-lactamases (MBLs) represents a major medical threat and there is an extremely urgent need to develop clinically useful inhibitors. We previously reported the original binding mode of 5-substituted-4-amino/H-1,2,4-triazole-3-thione compounds in the catalytic site of an MBL. Moreover, we showed that, although moderately potent, they represented a promising basis for the development of broad-spectrum MBL inhibitors. Here, we synthesized and characterized a large number of 4-amino-1,2,4-triazole-3-thione-derived Schiff bases. Compared to the previous series, the presence of an aryl moiety at position 4 afforded an average 10-fold increase in potency. Among 90 synthetic compounds, more than half inhibited at least one of the six tested MBLs (L1, VIM-4, VIM-2, NDM-1, IMP-1, CphA) with Ki values in the μM to sub-μM range. Several were broad-spectrum inhibitors, also inhibiting the most clinically relevant VIM-2 and NDM-1. Active compounds generally contained halogenated, bicyclic aryl or phenolic moieties at position 5, and one substituent among o-benzoic, 2,4-dihydroxyphenyl, p-benzyloxyphenyl or 3-(m-benzoyl)-phenyl at position 4. The crystallographic structure of VIM-2 in complex with an inhibitor showed the expected binding between the triazole-thione moiety and the dinuclear centre and also revealed a network of interactions involving Phe61, Tyr67, Trp87 and the conserved Asn233. Microbiological analysis suggested that the potentiation activity of the compounds was limited by poor outer membrane penetration or efflux. This was supported by the ability of one compound to restore the susceptibility of an NDM-1-producing E. coli clinical strain toward several β-lactams in the presence only of a sub-inhibitory concentration of colistin, a permeabilizing agent. Finally, some compounds were tested against the structurally similar di-zinc human glyoxalase II and found weaker inhibitors of the latter enzyme, thus showing a promising selectivity towards MBLs.

1,2,4-Triazole-3-thione Compounds as Inhibitors of Dizinc Metallo-β-lactamases

Metallo-β-lactamases (MBLs) cause resistance of Gram-negative bacteria to β-lactam antibiotics and are of serious concern, because they can inactivate the last-resort carbapenems and because MBL inhibitors of clinical value are still lacking. We previously identified the original binding mode of 4-amino-2,4-dihydro-5-(2-methylphenyl)-3H-1,2,4-triazole-3-thione (compound IIIA) within the dizinc active site of the L1 MBL. Herein we present the crystallographic structure of a complex of L1 with the corresponding non-amino compound IIIB (1,2-dihydro-5-(2-methylphenyl)-3H-1,2,4-triazole-3-thione). Unexpectedly, the binding mode of IIIB was similar but reverse to that of IIIA. The 3 D structures suggested that the triazole–thione scaffold was suitable to bind to the catalytic site of dizinc metalloenzymes. On the basis of these results, we synthesized 54 analogues of IIIA or IIIB. Nineteen showed IC50 values in the micromolar range toward at least one of five representative MBLs (i.e., L1, VIM-4, VIM-2, NDM-1, and IMP-1). Five of these exhibited a significant inhibition of at least four enzymes, including NDM-1, VIM-2, and IMP-1. Active compounds mainly featured either halogen or bulky bicyclic aryl substituents. Finally, some compounds were also tested on several microbial dinuclear zinc-dependent hydrolases belonging to the MBL-fold superfamily (i.e., endonucleases and glyoxalase II) to explore their activity toward structurally similar but functionally distinct enzymes. Whereas the bacterial tRNases were not inhibited, the best IC50 values toward plasmodial glyoxalase II were in the 10 μm range.

Molecular structure and conformation of the (Z) and (E) geometric isomers of 2-(2-phenylbenzylidene)-3 quinuclidinone

The crystal structures of the (Z) and (E) geometric isomers of 2-(2-phenylbenzylidene)-3-quinuclidinone were solved by direct methods, using diffractometric data, and refined to final R values of 0.040 and 0.061. The molecules of the (Z) and (E) geometric isomers show trans and cis conformation of the substituents around the double bond, respectively. The quinuclidine and the diphenyl moieties show deformations in their geometric and conformational parameters due to the need of releasing intramolecular strains and/or non-bonded interactions.

PHOTOLYTIC GENERATION OF N-ACYLNITRENIUM IONS UNDER NEUTRAL CONDITIONS: SYNTHESIS OF POLYCYCLIC LACTAMS

Intramolecular electrophilic aromatic acylamination has been achieved by the photolysis of N-aroylaminopyridinium tetrafluoroborates under neutral conditions.Acylnitrenium ions were most likely generated which substituted the adjacent ring without undergoing Curtius-type rearrangement.

Synthesis and neurokinin antagonist activity of 2-benzylidene- and 2- benzyl-3-benzylamino quinuclidines

Molecular modeling studies based on the potent NK-1 antagonist CP-96,345 led us to the identification of some 2-benzylidene- and 2-benzyl-3- benzylaminoquinuclidine derivatives as potential antagonists at the NK receptor subtypes. The synthesized compounds, whose Z/E isomerism has been defined by X-ray analysis, show only moderate potency on the three neurokinin receptors. The possible reasons of the low potency exhibited by the tested compounds are discussed.